KPRX

+ Watchlist + Portfolio

Kiora Pharmaceuticals, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.58
52-Week Range: $1.77 – $2.95
Market Cap: $11.33M
P/E (TTM): —
EPS (TTM): -2.46
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.67
PEG Ratio: —
Return on Equity: -56.36%
Return on Assets: -21.92%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 8.97
Debt/Equity: 0.02
Total Debt: $333.02K
Free Cash Flow: $-6.36M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-215.69K

KPRX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$16.00M	$0.00
Research & Development	$3.45M	$4.03M	$4.90M	$3.71M
Selling, General & Admin	$8.28M	$4.66M	$5.54M	$5.75M
Operating Expenses	$11.73M	$8.69M	$10.42M	$9.46M
Operating Income	-$11.73M	-$8.69M	$5.58M	-$9.46M
EBITDA	-$13.65M	-$12.36M	$5.70M	-$12.07M
Pretax Income	-$13.70M	-$12.42M	$5.66M	-$12.12M
Income Tax	-$113.01K	$90.32K	$2.07M	-$1.28M
Net Income	-$13.58M	-$12.51M	$3.59M	-$10.84M
Diluted EPS	-166.95	-24.25	0.87	-2.64
Diluted Shares	81366	538007	4.13M	4.17M

KPRX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$5.96M	$2.45M	$3.79M	$8.70M
Receivables	$1.37M	$2.05M	$871.44K	$3.32M
Current Assets	$7.68M	$4.74M	$29.71M	$21.75M
Total Assets	$18.68M	$13.71M	$36.48M	$24.25M
Current Liabilities	$3.27M	$1.63M	$6.01M	$3.63M
Total Debt	$105.78K	$106.89K	$57.17K	$368.26K
Total Liabilities	$7.27M	$7.60M	$10.72M	$8.13M
Retained Earnings	-$134.46M	-$146.98M	-$143.38M	-$154.22M
Shareholders' Equity	$11.41M	$6.11M	$25.76M	$16.13M
Working Capital	$4.41M	$3.10M	$23.70M	$18.12M

KPRX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$10.43M	-$9.56M	$8.56M	-$9.96M
Capital Expenditure	—	—	-$6.26K	-$110.79K
Free Cash Flow	-$10.43M	-$9.56M	$8.55M	-$10.07M
Depreciation & Amortisation	$41.61K	$51.80K	$19.20K	$24.80K
Stock-Based Compensation	$462.45K	$754.94K	$656.59K	$900.24K
Investing Cash Flow	$6.38K	$0.00	-$22.66M	$14.43M
Financing Cash Flow	$8.62M	$5.97M	$15.50M	$265.65K
Share Repurchases	-$15.63K	$0.00	—	—
Net Change in Cash	-$1.80M	-$3.59M	$1.39M	$4.73M

KPRX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$565.76K	$904.57K	$1.07M	$1.17M	$890.50K	$740.85K
Selling, General & Admin	$1.49M	$1.35M	$1.44M	$1.46M	$1.61M	$1.38M
Operating Expenses	$2.06M	$2.26M	$2.52M	$2.63M	$2.50M	$2.12M
Operating Income	-$2.06M	-$2.26M	-$2.52M	-$2.63M	-$2.50M	-$2.12M
EBITDA	-$2.05M	-$2.25M	-$2.50M	-$5.26M	-$2.49M	-$2.11M
Pretax Income	-$2.07M	-$2.26M	-$616.32K	-$7.17M	-$2.42M	-$2.08M
Income Tax	$123.01K	-$112.06K	-$643.13K	-$649.97K	$0.00	$0.00
Net Income	-$2.19M	-$2.15M	$26.81K	-$6.52M	-$2.42M	-$2.08M
Diluted EPS	-0.52	-0.54	0.01	—	-0.58	-0.34
Diluted Shares	4.22M	3.99M	4.36M	—	4.17M	6.18M

KPRX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$3.77M	$1.03M	$5.51M	$8.70M	$10.96M	$7.08M
Receivables	$2.06M	$3.11M	$2.67M	$3.32M	$3.45M	$2.91M
Current Assets	$27.11M	$24.74M	$22.69M	$21.75M	$18.68M	$21.26M
Total Assets	$34.02M	$31.95M	$29.86M	$24.25M	$21.23M	$23.78M
Current Liabilities	$5.27M	$3.19M	$2.58M	$3.63M	$2.80M	$2.37M
Total Debt	$159.02K	$430.41K	$404.17K	$368.26K	$373.59K	$333.02K
Total Liabilities	$10.32M	$9.82M	$7.45M	$8.13M	$7.29M	$6.92M
Retained Earnings	-$145.58M	-$147.73M	-$147.70M	-$154.22M	-$156.64M	-$158.71M
Shareholders' Equity	$23.70M	$22.13M	$22.41M	$16.13M	$13.93M	$16.86M
Working Capital	$21.83M	$21.55M	$20.11M	$18.12M	$15.88M	$18.89M

KPRX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$2.70M	-$3.80M	-$1.27M	-$2.18M	-$3.16M	-$1.89M
Capital Expenditure	—	—	-$431.00	-$78.16K	-$5.02K	-$23.46K
Free Cash Flow	-$2.70M	-$3.84M	-$1.27M	-$2.26M	-$3.17M	-$1.92M
Depreciation & Amortisation	$318.00	$3.42K	$10.55K	$10.51K	$10.56K	$10.74K
Stock-Based Compensation	$148.62K	$262.77K	$254.40K	$234.45K	$209.51K	$109.31K
Investing Cash Flow	$2.67M	$664.17K	$5.74M	$5.35M	$5.40M	-$6.89M
Financing Cash Flow	$0.00	$265.36K	$0.00	$296.00	-$842.00	$4.92M
Share Repurchases	$0.00	—	—	—	—	—
Net Change in Cash	-$31.42K	-$2.87M	$4.47M	$3.17M	$2.24M	-$3.86M

Market Snapshot

About

Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing therapies for ophthalmic diseases. The company focuses on treating retinal diseases and other sight-threatening eye conditions. Their pipeline includes novel small molecule compounds and drug delivery technologies designed to address significant unmet medical needs in ophthalmology.